29,989 Shares in CoLucid Pharmaceuticals Inc (CLCD) Acquired by Allianz Asset Management AG

Allianz Asset Management AG bought a new position in CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) during the fourth quarter, Holdings Channel reports. The fund bought 29,989 shares of the biopharmaceutical company’s stock, valued at approximately $1,092,000.

Other hedge funds also recently bought and sold shares of the company. BVF Inc. IL bought a new stake in CoLucid Pharmaceuticals during the third quarter worth about $29,120,000. FMR LLC boosted its stake in CoLucid Pharmaceuticals by 68.3% in the fourth quarter. FMR LLC now owns 1,318,727 shares of the biopharmaceutical company’s stock worth $48,002,000 after buying an additional 535,331 shares in the last quarter. Great Point Partners LLC bought a new stake in CoLucid Pharmaceuticals during the third quarter worth about $15,260,000. Marshall Wace LLP boosted its stake in CoLucid Pharmaceuticals by 170.7% in the fourth quarter. Marshall Wace LLP now owns 485,824 shares of the biopharmaceutical company’s stock worth $17,684,000 after buying an additional 306,344 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in CoLucid Pharmaceuticals during the third quarter worth about $11,445,000. Institutional investors own 64.17% of the company’s stock.

Institutional Ownership by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) opened at 46.525 on Tuesday. CoLucid Pharmaceuticals Inc has a 52 week low of $5.26 and a 52 week high of $46.65. The firm has a 50-day moving average of $44.95 and a 200 day moving average of $33.88.

Your IP Address:

A number of analysts have recently issued reports on CLCD shares. Zacks Investment Research cut shares of CoLucid Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 10th. Barclays PLC started coverage on shares of CoLucid Pharmaceuticals in a research note on Thursday, December 15th. They set an “overweight” rating and a $45.00 target price for the company. William Blair cut shares of CoLucid Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 18th. BTIG Research started coverage on shares of CoLucid Pharmaceuticals in a research note on Thursday, December 22nd. They set a “buy” rating and a $58.00 target price for the company. Finally, Piper Jaffray Companies cut shares of CoLucid Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $49.00 to $46.50 in a research note on Wednesday, January 18th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $46.92.

In other CoLucid Pharmaceuticals news, CEO Thomas P. Mathers sold 1,502 shares of the company’s stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $34.78, for a total transaction of $52,239.56. Following the transaction, the chief executive officer now owns 258,021 shares in the company, valued at $8,973,970.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Bernice Kuca sold 772 shares of the company’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $36.25, for a total transaction of $27,985.00. Following the transaction, the insider now owns 40,086 shares in the company, valued at approximately $1,453,117.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,327 shares of company stock worth $224,385. Corporate insiders own 13.70% of the company’s stock.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Want to see what other hedge funds are holding CLCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD).

Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.